Bromsite has one drug patent, none of which have already expired. The potential release date for Bromsite generic could be after August 7, 2029.
Bromsite is primarily used for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. It's effectiveness can be attributed to its active ingredient, bromfenac sodium.
Bromsite holds a patent titled 'Non-steroidal anti-inflammatory ophthalmic compositions', which expires on August 7, 2029. This patent could potentially delay the release of Bromsite generic. Below are the details of the patent: